Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 9 December 2025 - 10 December 2025

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Updated: December 10, 2025 Johnson & Johnson (NYSE: JNJ) is trading near fresh highs as investors weigh powerful growth drivers in oncology and immunology against a still‑messy overhang from talc litigation. As of late trading on December 10, 2025, JNJ changes hands around $203–204 per share, up roughly 1.9% on the day, with an intraday high just above $204 and…
10 December 2025
····
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda and the broader pipeline. As of late trading on December 10, 2025, Merck stock changes hands around $97.27, up slightly…
10 December 2025
····
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk stock is having a very noisy December 10, 2025. American depositary shares of Novo Nordisk A/S (ticker NVO) recently traded around $48 in New York, up roughly 3–4% intraday, with the session range hovering between about $47 and $48.3. That rebound comes after months of brutal underperformance and a barrage of fresh news: an M&A deal closing, obesity…
10 December 2025
····
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

December 10, 2025 – New York / Tel Aviv Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per…
10 December 2025
····
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Updated: December 10, 2025 Key takeaways LLY stock today: price, performance and valuation snapshot As of mid‑day trading on December 10, 2025, Eli Lilly (NYSE: LLY) is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending…
10 December 2025
····
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is back on traders’ radar as a late‑stage CNS biotech preparing for a potential New Drug Application (NDA) in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside targets. As of mid‑session on December 10, 2025, RVPH is trading around $0.69 per share, up roughly 10% on the…
10 December 2025
··
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options.…
10 December 2025
····
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance. Stock Titan Below is a deep dive…
10 December 2025
····
Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the day, after trading between an intraday low of $96.06 and a high of $99.85. Volume was elevated at about 15.3…
10 December 2025
··
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

HUNTSVILLE, Ala. — December 9, 2025 Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state leaders are calling the largest initial private industrial investment in Alabama history. City of Huntsville The facility, planned for a…
10 December 2025
·
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) has quietly turned into one of 2025’s wilder biotech stories: a tiny oncology name that’s run more than eightfold off its 52-week low, pulled back on a big equity raise, and now sits in the middle of a high-stakes bet on a single breast-cancer drug. Below is a structured look at OLMA stock today, the…
9 December 2025
···
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc. As of intraday…
9 December 2025
···
1 … 28 29 30 31 32 … 46

Stock Market Today

  • Palo Alto Networks (PANW) Valuation: Price Declines Amid High P/E Ratio Raise Questions
    January 22, 2026, 5:45 PM EST. Palo Alto Networks (PANW) shares have recently fallen, with declines over the past week, month, and three months, despite strong long-term returns of 139% over three years and 225% over five. The stock trades at $181.47 with a price-to-earnings (P/E) ratio of 113.2x, far exceeding the U.S. software industry average of 30.1x and peer average of 39x, indicating elevated market expectations for growth. A discounted cash flow (DCF) model suggests the stock may be undervalued at a 26.6% discount to intrinsic value ($247.24). Investors face a dilemma between high valuation multiples and DCF undervaluation amid recent price softness, highlighting cautious sentiment's impact on this cybersecurity leader.
Go toTop